Therapy: SGLT inhibition in T1DM - definite benefit with manageable risk
- PMID: 29076505
- DOI: 10.1038/nrendo.2017.139
Therapy: SGLT inhibition in T1DM - definite benefit with manageable risk
Comment on
-
Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.N Engl J Med. 2017 Dec 14;377(24):2337-2348. doi: 10.1056/NEJMoa1708337. Epub 2017 Sep 13. N Engl J Med. 2017. PMID: 28899222 Clinical Trial.
-
Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.Lancet Diabetes Endocrinol. 2017 Nov;5(11):864-876. doi: 10.1016/S2213-8587(17)30308-X. Epub 2017 Sep 14. Lancet Diabetes Endocrinol. 2017. PMID: 28919061 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical